US Proposes Investment Curbs on Chinese Biotech Firms

The US Treasury Department on Thursday proposed adding biotechnology to its list of sensitive technologies subject to investment limits involving foreign adversaries. The move would require American investors to notify the government about certain transactions involving foreign companies developing sensitive technologies — and prohibit others outright.

For practitioners, the practical question is obvious: what does this change for dealmaking? In the near term, less than the headlines suggest. The rules expand an existing program that already covers artificial intelligence, semiconductors and quantum computing. Equity investments and joint ventures are the transaction types most clearly affected, according to Duane Wright, a senior healthcare policy analyst at Bloomberg Intelligence.

Licensing deals, the lifeblood of US-China pharma ties, aren't expressly prohibited under the proposed rules, Wright said. That's the critical carve-out, because US drugmakers now lean heavily on China to replenish their pipelines. Chinese biotech companies have become a genuine source of innovation, and American pharmaceutical firms increasingly license promising treatments there as they hunt for new products.

How Did Markets React?

Shares of Chinese biotech companies fell on the news. Genscript Biotech Corp dropped as much as 14% in Hong Kong — the sharpest move of the group. Insilico Medicine Cayman TopCo slid 5.2%, Duality Biotherapeutics Inc fell 3.9%, and CSPC Pharmaceutical Group Ltd lost 3.4%. Jiangsu Hengrui Pharmaceuticals Co declined 3%, and Innovent Biologics Inc slipped 2.2%.

A 14% single-day drop is a loud signal, even if the rules themselves aren't final. The restrictions won't take effect until the rule-making process is complete.

How Broad Is the Definition?

Broad — deliberately so, at this stage. Wright noted the Treasury proposal starts with a "very broad definition" of biotechnology, covering small molecules, biologics, vaccines and cell and gene therapies. But it leaves room to narrow the pharmaceutical provisions after stakeholder comments.

"This is still the opening stage of the rule-making, so the scope could change before the rule is finalised," Wright said.

The proposal would also restrict investment in Chinese brain-computer interface companies. Both countries have burgeoning brain tech industries, with start-ups racing to develop implants, helmets and other devices that let people control electronics directly with their brains.

What's the Track Record?

This is the latest escalation in Washington's effort to rein in China's biotech advances. Last year, Congress passed the Biosecure Act, which restricts federal agencies and government-funded companies from using or procuring services from designated Chinese biotech firms. Notably, those restrictions ended up weaker and narrower than initially proposed — a precedent that suggests industry pushback can reshape the final text.

Beijing is adjusting its own posture too. Last week, China proposed adding several biomedical technologies to its export-control list. Its plan, however, explicitly allows licensing deals for drugs to continue — a sign that both governments want to protect the licensing channel even as they tighten everything around it.

What Are Industry Groups Saying?

The Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization (BIO), and Incubate, a coalition of life sciences venture capital investors, have all warned that an overly broad approach could backfire on American biotech companies and public health.

"The details of the proposed Treasury Department rules matter," John Crowley, president of BIO, said in a statement. "We cannot restrict our way to success."

That's the tension to watch. The Treasury wants national security guardrails; industry wants the licensing flow and innovation pipeline preserved. With the definition starting broad and stakeholder comments still ahead, the final scope of the biotech provisions — and whether licensing stays untouched — will determine how much capital actually retreats from the sector.